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Introduction
Type 1 diabetes mellitus is characterized by 
impaired insulin secretion. According to the 
World Health Organization report, 422 million 
people are diagnosed with diabetes, globally.1 The 
International Diabetes Federation reports an esti-
mated 1.11 million children and adolescents aged 
< 20 years have type 1 diabetes, with 132,600 new 
cases diagnosed annually from children and ado-
lescents of the age group < 20 years, worldwide, in 
2017.2 Moreover, the overall annual incidence of 
type 1 diabetes among children and adolescents 
has been estimated at around 3%.2 Therefore, 
treatment of diabetes among children remains one 
among the global health priorities.
About 14% of children achieve the glycated 
hemoglobin (HbA1c) target of <7.5% compared 
with 30% of adults (HbA1c target of <7.0%).3 
Challenges relating to the poor treatment out-
comes among children and adolescents with type 
1 diabetes have contributed, including noncom-
pliances and nocturnal hypoglycemic episodes, 
and a very close parental/guardian supervision is 
very much needed.3–5 However, improved and 
novel technologies including the use of insulin 
pens, insulin pumps, sensor-augumented pumps 
(SAPs) and artificial pancreas system improve the 
safety, effectiveness, and adherence to insulin 
regimen among children and adolescents with 
type 1 diabetes.6–13 In addition, automated mod-
ulating insulin-delivery systems according to the 
measured glucose levels under minimal supervi-
sion are particularly needed in alleviating the 
insulin delivery challenges.3,7 This necessitates 
the need for reviewing advanced technologies 
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addressing challenges associated with insulin 
delivery systems among children and adolescents 
with type 1 diabetes.
Nevertheless, vial-and-syringe method has been a 
conventional effective insulin treatment method 
among children and adolescents with type 1 dia-
betes to control HbA1c levels.14 However, main-
taining good glycemic control in children and 
adolescents might be affected by inaccurate dos-
ing, pain, fear of injection (needle phobia), 
acceptability, and inconveniences, as far as the 
standard vial-and-syringe-delivery method is con-
cerned.4,14,15 These drawbacks promoted the 
necessity for alternative insulin delivery methods 
such as insulin pens, insulin pumps, closed-loop 
‘artificial pancreas’ systems, and other insulin 
delivery routes including oral, inhalation, and 
nasal routes.8,9,11,16–20 This review article explores 
the current advances in the insulin delivery meth-
ods that address the needs of children and adoles-
cents in the treatment of type 1 diabetes.
Materials and methods
The search terms ‘vial and syringes,’ ‘insulin pen,’ 
‘insulin pump,’ ‘hybrid closed loop,’ ‘oral insulin,’ 
‘nasal insulin,’ ‘inhaled insulin,’ ‘type 1 diabetes,’ 
‘children,’ ‘adolescents,’ and other acronyms were 
used in combination with the Boolean operators 
as described by Boell and Cecez-Kecmanovic21 in 
identifying articles that were included in this 
review. Two authors (ZZ and WL) independently 
searched for the relevant articles written in 
English language up to June 2019 in the Ovid 
Medline, PubMed, and Google scholar electronic 
databases. Furthermore, the searches were sup-
plemented through scanning citations for the rel-
evant articles.
Current insulin-delivery methods for 
children and aldolescents with type 1 
diabetes
Vial and syringe
The standard injection (SIs) using vial and syringe 
is considered as effective means of delivering 
insulin among children and adolescents with type 
1 diabetes. Several modifications of modern 
syringes for insulin-delivery dates back to the 
early 19th century.22 However, invasiveness and 
needle phobia have been associated with patients 
compliance, resulting in higher HbA1c levels and 
infrequent blood glucose monitoring among chil-
dren and adolescents with type 1 diabetes.4,15
Insulin pens
Inaccuracy and inconvenience are the common 
challenges of the vial and syringe in setting up the 
insulin dose for many patients, including children 
and adolescents.14 These drawbacks of the vial 
and syringe led to manufacturing of insulin pens. 
The unveiling of NovoPen® (NovoNordisk A/S, 
Bagsvaerd, Denmark) in the mid-1980s by Novo 
Nordisk established another platform in diabetes 
treatment regimes as an alternative to the vial-and-
syringe method.23,24 Over the past 30 years after 
launching Novopen®, there have been several 
modifications by various pharmaceutical industries. 
Insulin pens are more accurate, user friendly (with 
less fear of injections), and associated with low pain 
when used with short and fine needles.8,9,24–26
NovoPen Echo® (NovoNordisk A/S, Bagsvaerd, 
Denmark) has merged two features, memory 
function, and half-unit increments dosing. It is a 
user-friendly, long-lasting insulin pen tailored for 
the pediatric population.24 The REMIND study 
evaluated the safety, usefulness of memory func-
tion, and users’ preferences of the NovoPen 
Echo® insulin pen in children and adolescents 
with type 1 diabetes (n = 315) aged 2–18 years 
from Canada, Finland, Israel, and Sweden. The 
study found that 99% of the patients reported the 
device was easy to read for the last-dose amount, 
and the vast majority of the patients were 
impressed by the safety, appearance, and user 
friendliness of the device.6 Likewise, the number 
of patients achieving 558 mmol/mol (7.5%) 
HbA1c decreased from 23.4% to 17.8% while the 
mean HbA1c levels increased by 2.7%.6 Moreover, 
Olsen and colleagues9 assessed the usefulness, 
functionality, and attitudes towards the NovoPen 
Echo® against NovoPen® (NovoNordisk A/S, 
Bagsvaerd, Denmark) Junior and HumaPen® 
Luxura (Eli Lilly and Company, Indianapolis, 
IN, USA) HD in children and adolescents aged 
7–18 years who received insulin treatment for less 
than 6 months in Germany, France, and Canada. 
They found that NovoPen Echo® was easy to set 
up, adjust, and inject insulin, and it was also more 
acceptable to children and adolescents, their par-
ents, and healthcare practitioners than other pen 
devices (NovoPen® Junior and HumaPen® 
Luxura HD).9,27 However, HumaPen® 
Luxura HD might be useful to children with 
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type 1 diabetes who need precise half-unit incre-
ment dosing.26,28
Another insulin pen, JuniorSTAR® (Sanofi-
Aventis, Paris, France), is a reusable insulin pen 
with half-unit increments developed for meeting 
the needs for young people with diabetes.8 
Another evaluation study on the usefulness of the 
JuniorSTAR® insulin pen in young people (2–
18 years) with type 1 diabetes involving both 
patients/parents and nurses found that ⩾87% of 
study participants (n = 167) agreed that it was 
easy to read and dial back when setting the dose, 
which help patients achieve high dosing accuracy 
in young people with type 1 diabetes.8 Therefore, 
the use of JuniorSTAR® by both young people 
with type 1 diabetes and their caregivers was con-
sidered more convenient and highly suitable for 
young people’s lifestyle.
The InPen® (Companion Medical, San Diego, 
CA, USA) system is a first US Food and Drug 
Administration (FDA)-approved smart pen for 
insulin management; it was launched in 2017 and 
uses Bluetooth® technology. It could help chil-
dren and their caregivers in constant tracking, 
monitoring, and calculating the required amount 
of insulin therapy, particularly because of its sim-
ple design and the half-unit adjustments needed 
by most children with diabetes.29,30
Injection ports
In addressing the invasiveness and needle phobia 
of SI, an insulin injection port called i-Port 
Advance® (Medtronic, Northridge, CA, USA) 
was developed in order to improve medication 
adherence.31 The i-Port Advance® rises to about 
9.3 mm above the skin when applied, with a flex-
ible cannula either 6 mm or 9 mm long for deliv-
ery of medication.31 Very limited information 
exists on suitability of i-Port Advance® in chil-
dren and adolescents with type 1 diabetes. 
However, regular use of the i-Port Advance® has 
been reported to improve patients’ compliance, 
reduce the chances of being hospitalized and 
finally, leading to rare hypoglycemic events, with 
a nonsignificant 0.73/100 reduction in HbA1c lev-
els among patients with diabetes with mean age 
14.96 ± 8.95 years.32 Meanwhile, the I-Port® 
device (Patton Medical Devices, Austin, Texas, 
USA) was recommended for children and adoles-
cents with type 1 diabetes in home and healthcare 
settings.33 Blevins and coworkers reported that 
I-Port® may be used for the administration of 
multiple insulin doses using a single I-Port® 
device, and concluded it was a feasible alternative 
to SI.33 In that context, both i-Port Advance® 
and I-Port® devices may be helpful in reducing 
needle phobia, and effectively achieving glycemic 
control among children and adolescents needing 
insulin therapy.
Insulin pumps
Unlike insulin pens, physiological delivery of insu-
lin is considered crucial in the management of type 
1 diabetes in children and adolescents. Continuous 
subcutaneous insulin fusion (CSII) or insulin-
pump therapy is coupled by a small, portable elec-
tronic pump for infusing insulin at a slow basal rate, 
considered ideal for titrating doses of insulin in chil-
dren and adolescents to avoid hypoglycemia.14,29 
Several insulin pumps are now available with built-
in features; blood-glucose monitoring (BGM) and 
continuous-glucose- monitoring (CGM) systems 
for infusing insulin in patients with type 1 diabetes 
(Table 2). However, these insulin pumps can be 
mutually and inclusively used with children and 
adolescents with type 1 diabetes, except MiniMed 
670G (Medtronic, Northridge, CA, USA), which is 
recommended for children aged 7 years and above.
Several studies have shown the effectiveness of 
CSII against multiple daily injection (MDI) in 
children and adolescents.10,13,16,57 A cross- 
sectional study by Szypowska and colleagues13 
compared the metabolic control in 16,570 chil-
dren with type 1 diabetes aged between 0 and 
18 years of age that were treated with CSII ver-
sus MDI in 46 SWEET centres. This study 
reported the adjusted HbA1c levels and daily 
insulin intake {CSII: 7.7 (7–8.5)%, [60.7 (53–
69) mmol/mol] versus MDI: 8.0 (7.2–9.1)%, 
[63.9 (55–76) mmol/mol], p < 0.0001} and 
[CSII: 0.83 (0.66–1.02) U/kg/d versus MDI: 0.9 
(0.7–1.13) U/kg/d, p < 0.0001] were signifi-
cantly reduced in children in the CSII group 
than MDI group, respectively.13
However, in a meta-analysis performed to evalu-
ate the effectiveness of CSII against MDI in chil-
dren with type 1 diabetes, there was a significant 
reduction in HbA1c levels for CSII compared with 
MDI (p = 0.007 and p = 0.006, respectively).10,57 
Similarly, a transatlantic study involving 54,410 
children and adolescents with type 1 diabetes 
aged under 18 years from three pediatric registries 
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combined [the US T1D (type 1 diabetes) 
Exchange, the English-Welsh National Pediatric 
Diabetes Audit and the German–Austrian Pro-
spective Diabetes Follow-up Registry] reported 
unadjusted HbA1c levels in CSII users 8.0 ± 1.2% 
(64 ± 13.3 mmol/mol) were considerably lower 
than MDI users 8.5 ± 1.7% (69 ± 18.7 mmol/
mol), p < 0.001.11 Nevertheless, girls were more 
likely to use CSII pump therapy compared with 
boys [odds ratio (OR): 1.22, 95% confidence 
interval (CI): 1.17–1.27].11 Despite insulin 
pumps improving insulin effectiveness, they have 
been reported to increase the incidence of ketoac-
idosis in children and adolescents with type 1 dia-
betes approximately six times more in the CSII 
group than in the MDI group.16
Sensor-augmented pump
Another milestone in the management of type 1 
diabetes in children and adolescents involves the 
integration of CGM and insulin-pump (or CSII) 
technologies. When CGM and CSII are coupled, 
it is sometimes referred to as a SAP. However, 
CGM and MDI can altogether be useful in opti-
mizing metabolic levels.29 A randomized con-
trolled trial investigated the predictive low-glucose 
management (PLGM) of the MiniMedTM 
640 (Medtronic, Watford, Hertfordshire, UK) 
device in reducing hypoglycemia rates in com-
parison with the SAP in 100 children and adoles-
cents (aged 8–18 years) with type 1 diabetes who 
were clinically based at two sites, each from 
Israel and Slovenia. This study showed reduced 
Table 1. Comparison of popular insulin pens for use in children and adolescents with type 1 diabetes.14










AutoPen® Owen Mumford, Oxford, 
UK
Reusable No 1.0 – Owen Mumford 
Ltd34
NovoPen Echo® Novo Nordisk A/S, 
Bagsværd, Denmark
Reusable Yes 0.5 – Novo Nordisk A/S35
Novolog® 
Flexpen®
Novo Nordisk A/S, 
Bagsværd, Denmark
Disposable No 1.0 – Novo Nordisk A/S36
Tresiba 
FlexTouch®
Novo Nordisk A/S, 
Bagsværd, Denmark
Reusable No 1.0, 2.0 1+ Novo Nordisk A/S37
Levemir  
FlexTouch
Novo Nordisk A/S, 
Bagsværd, Denmark
Disposable No 1.0 2+ Novo Nordisk A/S38
Humalog® Junior 
KwikPen®
Eli Lilly and Company, 
Indianapolis, IN, USA




Eli Lilly and Company, 
Indianapolis, IN, USA




Eli Lilly and Company, 
Indianapolis, IN, USA
Reusable No 1.0 6+ Eli Lilly and 
Company41
JuniorSTAR® Sanofi-Aventis, Paris, 
France















Disposable No 1.0 4+ Sanofi-Aventis45
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hypoglycemic events at the expense of extended 
duration in moderate hypoglycemia below 
3.6 mmol/l in the PLGM on relative to PLGM 
off (mean ± standard deviation: 4.4 ± 4.5 versus 
7.4 ± 6.3, p = 0.008, respectively).5
Similarly, a home-based randomized crossover 
trial investigated the effectiveness and safety of 
integrated t:slim X2 pump with Dexcom G5 
sensor deploying PLGM against SAP therapy in 
adolescents, children, and adults with type 1 dia-
betes (n = 103, 6–72 years), and reported a signifi-
cant hypoglycemia reduction using the t:slim 
X2 Basal-IQ PLGM system.17 In this con-
text, a closed-loop insulin delivery system can 
reduce hypoglycemia risk, leading to improved 
metabolic control and reduced burden to chil-
dren with type 1 diabetes.5,17,18
Table 2. Comparison of mostly popular insulin pumps that can be used in children and adolescents with type 1 diabetes.


















































SOOIL Development Co., 
Ltd., Seoul, Korea





Roche Diabetes Care, Inc., 
Indianapolis, IN, USA




Roche Diagnostics Ltd., 
Burgess Hill, West 
Sussex, UK




Roche Diagnostics Ltd., 
Burgess Hill, West 
Sussex, UK
BGM 0.01–2.0* 0.01 – Roche Diagnostics 
Ltd.54
t:slim X2 Tandem Diabetes Care 
Inc., San Diego, CA, USA
CGM 0.5–5.0d 0.1 6+ Tandem Diabetes 
Care Inc.55
t:slim G4 Tandem Diabetes Care 
Inc., San Diego, CA, USA
CGM 0.5–5.0e 0.1 – Tandem Diabetes 
Care Inc.56
All information gathered in this table was obtained from the reference manual of each specified insulin-pump device.
*No specific increments were stated in the manual.
Specific increments were:
a0.025, 0.05 and 0.1;
b0.05, 0.1, 0.5 and 1.0;
c0.1, 0.2, 0.5, 1.0 and 2.0;
d0.01, 0.05 and 0.1 and e0.5, 1.0, 2.0 and 5.0. 
BGM, blood-glucose monitoring; CGM, continuous glucose monitoring.
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Future approaches for delivering insulin in 
children and adolescents with type 1 diabetes
Inhaled-insulin devices
Regardless of the wide availability of various 
inhaled-insulin devices on the market, they have 
not been widely recommended for application in 
children and adolescents with type 1 diabetes. 
Inhaled-insulin devices have been associated with 
technical challenges for children and adolescents 
with type 1 diabetes, including safety and poten-
tial side effects, such as hypoglycemia, cough and 
throat pain despite their non-invasive route of 
administration (Table 3).
The first FDA-approved inhaled insulin, known 
as Exubera® (EXU), was approved in January 
2006. Children and adolescents were, arguably, 
the group expected to benefit most from EXU by 
avoiding and minimizing injections.61 EXU was 
not approved for children aged < 18 years. 
However, a study by White and coworkers62 com-
pared the effectiveness and safety of EXU against 
subcutaneous insulin (SCI) in children with type 
1 diabetes aged 6–11 years, and reported an 
adjusted mean decrease in HbA1c levels [EXU − 
SCI], −0.23 (95% CI: −0.49 to 0.03). Additionally, 
mild–moderate cough was 3.6 times higher in the 
EXU than SCI patients. In that context, EXU was 
shown to be effective in reducing plasma glucose 
levels in children with type 1 diabetes.62 However, 
EXU was withdrawn from the market by Pfizer 
due to its poor market performance and unaccept-
ability among patients and physicians.22,63 As a 
result of this, a 12-month randomized, open-label 
phase III clinical trial [ClinicalTrials.gov identi-
fier: NCT00479258] assessing safety and effec-
tiveness of EXU in comparison with SCI therapy 
in type 1 diabetic children and adolescents (6–
17 years old) was also terminated.64
Another promising inhaled-insulin device, 
Afrezza®, a monomeric inhaled-insulin devel-
oped by Mannkind Corporation, was the second 
inhaled-insulin device approved by the FDA in 
June 2014.20,59 Nevertheless, Afrezza® was con-
ditionally approved for rapid-acting inhaled insu-
lin in improving postprandial (after meal) 
glycemic control in adults with either type 1 or 
type 2 diabetes but not in children.20 However, 
Mannkind Corporation is running a phase II clin-
ical trial in assessing the safety and tolerability of 
Afrezza® among children and adolescents aged 
4–17-years old with type 1 diabetes [ClinicalTrials.
gov identifier: NCT02527265].65
AERx® insulin diabetes management system 
(iDMS) is another inhaled-insulin device that gen-
erates liquid aerosol with consistent 2–3 µm-sized 
particles.63 Unlike EXU and Afrezza® inhaled-
insulin devices, very limited information exists 
concerning the safety and efficacy of the AERx® 
iDMS among adolescents and children with type 
1 diabetes. However, a randomized, parallel clini-
cal trial assessing the safety and effectiveness of 
AERx® iDMS with SCI therapy in patients with 
type 1 diabetes aged between 18 and 81-years old 
reported differences in HbA1c levels (AERx® 
iDMS–SCI), 0.18% (95% CI: −0.04 to 0.39) 
while the fasting plasma glucose was significant 
lower in the AERx® iDMS group than the SCI 
group (9.2 mmol/l versus 11.7 mmol/l, p < 0.001).63 
Additionally, reduced percentage difference of the 
predicted lung diffusing capacity for carbon 
monoxide, using AERx® iDMS was −2.03%, 
p = 0.04, which occurred after 3 months and then 
Table 3. Selected types of inhaled insulin and their actions.









Exubera® Dry powder 5–6 h Hypoglycemia, 
cough, sore throat




Afrezza® Dry powder 2–3 h Hypoglycemia, 
cough, throat pain 
or irritation
FDA approved, 
available on the 
market
No Klonoff59




No Wollmer et al.60
FDA, US Food and Drug Administration; iDMS, insulin diabetes management system.
Z Zuberi, E Sauli et al.
journals.sagepub.com/home/tae 7
stabilized.63 Furthermore, the findings from this 
clinical trial suggested that the effectiveness and 
safety of inhaled-insulin AERx® iDMS are com-
parable to the SCI Aspart, with further optimiza-
tion among adults with type 1 diabetes. Conversely, 
a phase III clinical trial [ClinicalTrials.gov identi-
fier: NCT00322257] comparing the effectiveness 
and safety of inhaled-insulin AERx® iDMS with 
SCI aspart, with each intervention grouped with 
insulin detemir among type 1 diabetic patients 
aged ⩾ 18 years, was terminated by Novo Nordisk 
A/S.66 The development of inhaled-insulin 
AERx® iDMS was discontinued by Novo Nordisk 
A/S due to inability to provide significant clinical 
benefits over the modern insulin pen devices, and 
not for safety reasons.63
Portal insulin delivery
The hepatic-directed vesicle (HDV) was devel-
oped by Diasome Pharmaceuticals Inc., 
Cleveland, Ohio, USA. It is a novel investiga-
tional insulin-delivery system with diameter < 150 
nm, capable of carrying any commercially availa-
ble insulin and a specific hepatocyte-targeting 
molecule remotely mimicking a portal vein insu-
lin infusion and a non-invasive oral route.67 
Meanwhile, the study findings of the InSulin 
Liver Effect (ISLE-1) phase IIb, multicenter, ran-
domized, double-blind clinical trial [ClinicalTrials.
gov identifier: NCT02794155] investigated the 
safety and efficacy of the hepatic-directed vesicle 
insulin lispro (HDV-L) against insulin lispro 
(LIS) in patients with type 1 diabetes over a 
26-week treatment period were a mean change in 
HbA1c levels of 0.09% (95% CI: 20.18–0.35) 
from baseline.68 Similarly, incidence rates of 
severe hypoglycemia among poorly controlled 
patients (HbA1c ⩾ 8.5%) and better-controlled 
patients (HbA1c < 8.5%) in HDV-L and LIS arms 
were (69 and 97, p = 0.03) versus (191 and 21, 
p = 0.001) events/100 person-years, respectively.69 
If the current trendline of the study findings con-
tinue in the upcoming phase III clinical trial, 
patients under insulin treatment would simulta-
neously achieve the target HbA1c levels and 
reduce hypoglycemic risks.
Oral insulin delivery
Various developmental challenges have been 
associated with rendering effectiveness of the oral 
route for insulin delivery. These include poor epi-
thelial permeability and enzymatic degradation of 
insulin in the gastrointestinal (GI) tract, leading 
to insufficient bioavailability of insulin.70 The oral 
route is considered an appropriate, convenient 
and safe route for insulin administration in chil-
dren and adolescents with type 1 diabetes.
Neither published evidence from clinical trials 
nor approved oral insulin therapy assessing the 
safety and effectiveness of oral insulin in the treat-
ment of type 1 diabetes in adolescents and chil-
dren is yet to be available. However, a pilot study 
conducted by Eldor and coworkers19 reported 
the treatment effect of ORMD-0801 in the glu-
cose reading frequencies > 200 mg/dl was associ-
ated with 24.4% reduction (60.7 ± 7.9% against 
45.4 ± 4.9% in pretreatment and in-treatment 
with ORMD-0801 respectively, p = 0.023) in 
patients with uncontrolled type 1 diabetes aged 
27–50-years old [ClinicalTrials.gov identifier: 
NCT00867594]. In the Pre-POINT randomized 
clinical trial [ClinicalTrials.gov identifier: 
NCT02620553] assessing the effects of high-dose 
oral insulin (from Lilly Pharmaceuticals) on the 
immune response in children (2–7 years) highly 
susceptible for type 1 diabetes, the day-to-day 
oral dosage of 67.5 mg insulin triggered immune 
response without inducing hypoglycemia.71 
However, the phase III clinical trial could help 
determine the prevention effect of this oral insulin 
against islet autoimmunity and type 1 diabetes 
among children of the same age.72
Recently, Abramson and colleagues70 developed 
an ingestible self-orienting millimeter-scale 
applicator (SOMA) system that directly engages 
with GI tissue for insulin delivery. In vivo studies 
in rats and pigs demonstrated the SOMA system 
to be safe and effective, of which the active insu-
lin levels were comparable with those adminis-
tered via the SCI route.70 Nevertheless, novel 
approaches for oral insulin development in over-
coming the GI tract’s harsh conditions need to be 
apprehended.
Buccal insulin delivery
The buccal route of administration helps to bypass 
the GI degradation, thus enhance bioavailability 
of the delivered biomolecules. Oral-lyn® (devel-
oped by Generex Biotechnology Corp., Toronto, 
Canada) is a short-acting insulin (in liquid formu-
lation) sprayed into the mouth using a proprietary 
RapidMist® device for management of type 1 and 
type 2 diabetes. Currently, there is no any ongoing 
Therapeutic Advances in Endocrinology and Metabolism 11
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clinical trial of the Generex Oral-lyn® involving 
children and adolescents with type 1 diabetes. 
Nevertheless, the study findings of a 26-week 
open-label, randomized, active comparator phase 
III clinical trial [ClinicalTrials.gov identifier: 
NCT00668850] compared the Oral-lyn® against 
a regular human insulin therapy as measured by 
HbA1c levels; the number of hypoglycemic epi-
sodes in patients with type 1 diabetes aged 18–
75 years are not yet disclosed.73 Recently, Generex 
Biotechnology Corp., announced reformulation 
of Altsulin® (microencapsulated sertoli cells) 
from its subsidiary ALTuCELL, Inc. for the treat-
ment of type 1 diabetes.74
Nasal insulin delivery
Intranasal insulin-delivery route is more advanta-
geous over the oral delivery route, as it has an 
ability to bypass GI peptidases, is non-invasive, 
painless, and no potential side effects have been 
associated with lung function.75 However, ineffi-
cient permeability of large molecules across the 
nasal mucosa and rapid mucociliary clearance, 
resulting in varied bioavailability of the active 
insulin in systemic circulation, are the drawbacks 
of the intranasal insulin delivery.75–77
Currently, a PINIT randomized phase II clinical 
trial [ClinicalTrials.gov identifier: NCT03182322] 
is testing the immune effectiveness and safety of 
intranasal insulin (440 IU) treatment in islet-auto-
immunity-negative children aged 1–7 years at high 
risk of having type 1 diabetes.78 However, an 
active randomized controlled phase II clinical trial 
[ClinicalTrials.gov identifier: NCT00336674] 
has determined the prevention effect of intranasal 
insulin (440 IU) in children and young adults aged 
4–30 years at risk of type 1 diabetes.79 Both these 
clinical trials use nasal spray Pfeiffer actuators in 
administering the 440 IU intranasal insulin, which 
contains recombinant human insulin, benzalko-
nium chloride, glycerol, and water. However, the 
results from these phase II clinical trials are 
awaited.
Future closed-loop systems
An automated insulin-delivery system (also called 
closed loop, artificial pancreas) combines an algo-
rithmic controller for subcutaneous estimation of 
the blood-glucose levels, computing and adminis-
tering insulin dosing commands using an insulin 
pump. The MiniMed 670G system (Medtronic, 
Northridge, CA, USA) became the first hybrid 
closed-loop system to get FDA approval.12 
However, several other automated closed-loop 
insulin-delivery systems are either in clinical trials 
or under development.
Recently, Brown and coworkers7 assessed the 
safety and efficacy of an automated insulin-deliv-
ery system that combines the t:slim X2 insulin 
pump, Dexcom G6 CGM, coupled with a built-
in Control-IQ algorithm among patients with 
type 1 diabetes aged 14–61 years (n = 168; 112 
were assigned to the closed-loop group and 56 in 
the control group) in a 6-month, multicenter, 
randomized trial [ClinicalTrials.gov identifier: 
NCT03563313].7 The study reported that the 
significant mean percentage difference of time 
(closed loop minus control) in the glucose target 
range of 80–180 mg/dl was 11% (95% CI: 9–14, 
p < 0.001).7 After 6 months, the mean adjusted 
difference in glycated hemoglobin HbA1c levels 
was −0.33% (95% CI: −0.53 to −0.13; p = 0.001).7 
Therefore, the greater percentage of time spent 
using the closed-loop system was strongly associ-
ated with the target glycemic range rather than 
the SAP. Yet, the study findings of the Control-
IQ among patients with type 1 diabetes aged 
14+ years had been submitted to the FDA for 
approval. In line with this, there is an ongoing 
clinical trial [ClinicalTrials.gov identifier: 
NCT03844789] assessing the safety and accept-
ance of the artificial pancreas, t:slim X2, incor-
porating Dexcom G6 CGM, coupled with a 
built-in Control-IQ technology for improving 
blood-glucose levels among children with type 1 
diabetes aged 6–13 years old.80
Nevertheless, an ongoing 6-month day-and-
night open-label, multicenter, multinational, 
single-period, randomized, parallel-group clini-
cal trial (DAN05) [ClinicalTrials.gov identifier: 
NCT02925299] assessing the efficacy, safety and 
usability of an automated closed-loop insulin 
delivery [FlorenceM in the US (MiniMed 640G 
insulin pump, Medtronic, CA, USA incorporat-
ing the Medtronic Guardian Sensor 3 CGM) 
and FlorenceX in the UK (Dana Diabecare® R 
insulin pump, SOOIL Development, Seoul, 
Korea, incorporating the Dexcom G6 CGM)] in 
comparison with the insulin-pump therapy by 
measuring HbA1c levels for controlling the blood 
glucose among children and adolescents (n = 130) 
with type 1 diabetes aged 6–18 years old.81,82 The 
DAN05 study is expected to be completed by 
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June 2020 and will measure both primary and sec-
ondary outomes. The primary outcome will involve 
the mean group differences in HbA1c levels at base-
line for the 6-month duration; while the secondary 
outcomes, such as the time spent between 70 mg/
dl and 180 mg/dl (3.9–10.0 mmol/l) glucose target 
levels, and time spent above or below the glucose 
target, as measured by CGMs and other related 
CGM metrics, will be documented.81,82
Currently, MiniMed 670G is the only auto-
mated insulin-pump system available on the mar-
ket which automatically adjusts basal insulin delivery 
depending on the CGM readings.12 In June 2019, 
Medtronic launched a home-based study trial 
[ClinicalTrials.gov identifier: NCT03959423] to 
evaluate the safety of the MiniMed 780G, 
advanced hybrid closed-loop sytem for automated 
basal insulin delivery in adult and pediatric par-
ticipants with type 1 diabetes aged 7–75 years 
(n = 250).83 The primary outcomes, including 
change in HbA1c levels, and mean difference in 
percentage of time spent between 70 mg/dl to 
180 mg/dl from baseline to the end of a 3-month 
study period will be measured, while the number 
of hypoglycemic events and diabetic ketoacidosis 
experienced by participants as the secondary out-
comes will also be evaluated.83
In a day-and-night, randomized crossover study 
trial [ClinicalTrials.gov identifier:
NCT02105324] with an automated artificial 
pancreas, bihormonal bionic pancreas (giving 
both insulin and glucagon hormones) from Beta 
Bionics Inc., Boston, MA, USA against the con-
ventional insulin-pump therapy in preadolescent 
children (n = 19, aged 6–11 years) with type 1 dia-
betes in a diabetes camp setting showed a signifi-
cant lower mean of the measured CGM glucose 
levels and time percentage of measured CGM glu-
cose levels < 3.3 mmol/l (7.6 ± 0.6 mmol/l versus 
9.3 ± 1.7 mmol/l, p = 0.00037 and 1.2 ± 1.1% ver-
sus 2.8 ± 1.2%, p < 0.0001) in the bionic pancreas 
period than the control period of 2–5 days, 
respectively.3 These findings highlight the need 
for investigational studies having a long duration 
to fully understand the bionic pancreas poten-
tials among children with type 1 diabetes in the 
real-world settings. Additionally, in a very 
recently completed day-and-night randomized 
crossover trial study [ClinicalTrials.gov identi-
fier: NCT04112069] testing the safety and effec-
tiveness of the 5-day insulin-only mode Gen3 
iLet (iLet) bionic pancreas using a Dexcom G5 
CGM against 5-day SAP therapy in children with 
type 1 diabetes and adolescents (n = 20, aged 
6–17 years).84 The prefindings showed that par-
ticipants achieved good glycemic control with the 
mean CGM glucose levels and the mean percent-
age time-in-range target glucose levels (70–180 mg/
dl) of 160 ± 27 mmol/l versus 163 ± 15 mmol/l; and 
65 ± 15% versus 65 ± 10% for SAP and iLet 
groups, respectively.85 Regardless of the improved 
glycemic control with low hypoglycemia levels, 
there were very few hyperglycemic events which 
led to the changes in the Gen4 iLet under develop-
ment in improving its safety and usability in the 
pedriatic population.
Nevertheless, Abbott Diabetes Care Inc., from 
Alameda, CA, USA and Bigfoot Biomedical Inc., 
from Milpitas, CA, USA collaborated in the devel-
opment of the smartloop automated insulin-
delivery system that automatically measures a 
patient’s blood-glucose levels every 15 min for up 
to 10 days.86 The study findings from a clinical 
trial [ClinicalTrials.gov identifier: NCT02849288] 
completed in 2016 that assessed the safety and 
feasibility of the smartloop automated insulin-
delivery system among patients aged 7+ years 
with type 1 diabetes are not yet disclosed.87 
However, the smartloop automated insulin-
delivery system is expected to be available in the 
market after FDA approval.
Conclusion and future prospects
The search for alternative insulin-delivery methods 
that have minimal invasiveness, convenient, safe, 
effective, and tailored for children and adolescent 
patients are considered of great importance. 
Insulin pens remain the alternative delivery device 
in children and adolescents with diabetes, as they 
continue to improve insulin treatment adherence 
over the traditional means of insulin administra-
tion using vial and syringes. Further advances on 
hybrid closed-loop ‘artificial pancreas’ system 
should be strongly emphasized, as this system has 
already shown significant metabolic control among 
children and adolescents with diabetes. In future, 
pain-free and non-invasive smart fitted patches of 
microneedles might influence insulin injection 
compliance and reduce anxiety in children and 
adolescents with type 1 diabetes.
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